CN114146227B - Preparation method of flexible directional nanofiber composite membrane capable of promoting vascular regeneration - Google Patents
Preparation method of flexible directional nanofiber composite membrane capable of promoting vascular regeneration Download PDFInfo
- Publication number
- CN114146227B CN114146227B CN202111177371.3A CN202111177371A CN114146227B CN 114146227 B CN114146227 B CN 114146227B CN 202111177371 A CN202111177371 A CN 202111177371A CN 114146227 B CN114146227 B CN 114146227B
- Authority
- CN
- China
- Prior art keywords
- gelatin
- methacrylic acid
- composite membrane
- proportion
- acid acylated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000012528 membrane Substances 0.000 title claims abstract description 58
- 239000002121 nanofiber Substances 0.000 title claims abstract description 43
- 239000002131 composite material Substances 0.000 title claims abstract description 34
- 230000001737 promoting effect Effects 0.000 title claims abstract description 16
- 230000008929 regeneration Effects 0.000 title claims abstract description 16
- 238000011069 regeneration method Methods 0.000 title claims abstract description 16
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 230000002792 vascular Effects 0.000 title claims abstract description 7
- 239000008273 gelatin Substances 0.000 claims abstract description 59
- 229920000159 gelatin Polymers 0.000 claims abstract description 59
- 108010010803 Gelatin Proteins 0.000 claims abstract description 47
- 235000019322 gelatine Nutrition 0.000 claims abstract description 47
- 235000011852 gelatine desserts Nutrition 0.000 claims abstract description 47
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims abstract description 34
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims abstract description 34
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims abstract description 34
- 229920001610 polycaprolactone Polymers 0.000 claims abstract description 17
- 239000004632 polycaprolactone Substances 0.000 claims abstract description 17
- 238000010041 electrostatic spinning Methods 0.000 claims abstract description 16
- DCUFMVPCXCSVNP-UHFFFAOYSA-N methacrylic anhydride Chemical class CC(=C)C(=O)OC(=O)C(C)=C DCUFMVPCXCSVNP-UHFFFAOYSA-N 0.000 claims abstract description 11
- 210000004204 blood vessel Anatomy 0.000 claims abstract description 9
- 238000011065 in-situ storage Methods 0.000 claims abstract description 6
- 238000003756 stirring Methods 0.000 claims description 55
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims description 46
- 238000000502 dialysis Methods 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 24
- 239000000017 hydrogel Substances 0.000 claims description 23
- 108010041308 Endothelial Growth Factors Proteins 0.000 claims description 21
- 239000008367 deionised water Substances 0.000 claims description 21
- 229910021641 deionized water Inorganic materials 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- 239000000243 solution Substances 0.000 claims description 20
- KHDZXBKJADQNKK-UHFFFAOYSA-N P(O)(O)O.C1(=CC=CC=C1)C=1C(=C(C(=O)[Li])C(=CC1C)C)C Chemical class P(O)(O)O.C1(=CC=CC=C1)C=1C(=C(C(=O)[Li])C(=CC1C)C)C KHDZXBKJADQNKK-UHFFFAOYSA-N 0.000 claims description 16
- 238000004108 freeze drying Methods 0.000 claims description 16
- 238000002156 mixing Methods 0.000 claims description 16
- 239000008363 phosphate buffer Substances 0.000 claims description 15
- 239000012266 salt solution Substances 0.000 claims description 14
- 239000000835 fiber Substances 0.000 claims description 12
- 238000006243 chemical reaction Methods 0.000 claims description 11
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 claims description 10
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 10
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 10
- 229940014800 succinic anhydride Drugs 0.000 claims description 10
- 238000010438 heat treatment Methods 0.000 claims description 9
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 claims description 8
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 claims description 7
- BYEAHWXPCBROCE-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-ol Chemical compound FC(F)(F)C(O)C(F)(F)F BYEAHWXPCBROCE-UHFFFAOYSA-N 0.000 claims description 5
- 230000003213 activating effect Effects 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 5
- 230000007480 spreading Effects 0.000 claims description 5
- 238000003892 spreading Methods 0.000 claims description 5
- 238000001291 vacuum drying Methods 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 3
- 238000007711 solidification Methods 0.000 claims description 2
- 230000008023 solidification Effects 0.000 claims description 2
- 230000033115 angiogenesis Effects 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 6
- 230000007547 defect Effects 0.000 abstract description 4
- 239000002114 nanocomposite Substances 0.000 abstract description 4
- 239000000758 substrate Substances 0.000 abstract description 3
- 230000021164 cell adhesion Effects 0.000 abstract description 2
- 239000003814 drug Substances 0.000 abstract description 2
- 230000010595 endothelial cell migration Effects 0.000 abstract description 2
- 230000035876 healing Effects 0.000 abstract description 2
- 230000035755 proliferation Effects 0.000 abstract description 2
- 230000001172 regenerating effect Effects 0.000 abstract description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 abstract description 2
- 230000008728 vascular permeability Effects 0.000 abstract description 2
- 239000002861 polymer material Substances 0.000 abstract 2
- 238000000016 photochemical curing Methods 0.000 abstract 1
- 238000009423 ventilation Methods 0.000 abstract 1
- 239000011148 porous material Substances 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 6
- 239000000126 substance Substances 0.000 description 5
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000001878 scanning electron micrograph Methods 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000003181 biological factor Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 239000003519 biomedical and dental material Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000001523 electrospinning Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 108010025899 gelatin film Proteins 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000004298 light response Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- -1 methacryloyl Chemical group 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/222—Gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/52—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/60—Materials for use in artificial skin
-
- D—TEXTILES; PAPER
- D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
- D01D—MECHANICAL METHODS OR APPARATUS IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS
- D01D5/00—Formation of filaments, threads, or the like
- D01D5/0007—Electro-spinning
- D01D5/0015—Electro-spinning characterised by the initial state of the material
-
- D—TEXTILES; PAPER
- D04—BRAIDING; LACE-MAKING; KNITTING; TRIMMINGS; NON-WOVEN FABRICS
- D04H—MAKING TEXTILE FABRICS, e.g. FROM FIBRES OR FILAMENTARY MATERIAL; FABRICS MADE BY SUCH PROCESSES OR APPARATUS, e.g. FELTS, NON-WOVEN FABRICS; COTTON-WOOL; WADDING ; NON-WOVEN FABRICS FROM STAPLE FIBRES, FILAMENTS OR YARNS, BONDED WITH AT LEAST ONE WEB-LIKE MATERIAL DURING THEIR CONSOLIDATION
- D04H1/00—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres
- D04H1/70—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres characterised by the method of forming fleeces or layers, e.g. reorientation of fibres
- D04H1/74—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres characterised by the method of forming fleeces or layers, e.g. reorientation of fibres the fibres being orientated, e.g. in parallel (anisotropic fleeces)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
- A61L2300/414—Growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/602—Type of release, e.g. controlled, sustained, slow
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/12—Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Textile Engineering (AREA)
- Mechanical Engineering (AREA)
- Dispersion Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Materials For Medical Uses (AREA)
Abstract
The invention discloses a preparation method of a flexible directional nanofiber composite membrane capable of promoting vascular regeneration, and belongs to the field of preparation of biological composite materials. The composite membrane has the effects of promoting cell adhesion, increasing vascular permeability, vascular endothelial cell migration, proliferation, angiogenesis and the like, combines the characteristics of porous ventilation and toughness, can be used as a wound dressing for a tissue defect part, and can be prepared in batches by promoting the regeneration of blood vessels at the defect part to enhance the healing capacity of wound tissue. The composite film has a double-layer structure: taking an electrostatic spinning flexible oriented nanofiber membrane of a synthetic high polymer material Polycaprolactone (PCL) and a natural high polymer material gelatin as a substrate; and (3) in-situ photocuring a layer of gelatin molecular skeleton of methacrylic anhydride modified and covalent grafted Vascular Endothelial Growth Factor (VEGF) on the membrane. The nano composite membrane has good biocompatibility and mechanical flexibility, and has good application prospect in regenerative medicine and clinical treatment.
Description
Technical Field
The invention relates to the technical field of biological material preparation, in particular to a preparation method of a flexible directional nanofiber composite membrane capable of promoting vessel regeneration.
Background
At present, a VEGF-loaded method is adopted in a lot of tissue engineering to promote the regeneration of blood vessels; the microsphere is used for loading VEGF to achieve a slow release effect, but the microsphere cannot imitate an extracellular matrix structure and can not effectively regulate migration and differentiation of cells at a wound on a microstructure; in researches related to nanofiber membranes, the method is basically limited to encapsulating and loading VEGF directly on the nanofiber membrane by an electrostatic spinning method, and in the process, the encapsulation efficiency of VEGF is difficult to ensure and the VEGF is possibly inactive due to electrostatic force or the action of an organic solvent; VEGF is also encapsulated in a simple hydrogel and acts directly on the wound site, but the breathability, tensile properties and degradation rate of the hydrogel are difficult to match with normal tissues.
The electrostatic spinning nanofiber has the advantages of good absorbability, selective permeability, good fitting property, multifunction, contribution to wound healing and the like. Because the diameter of the nanofiber is smaller than that of the cell, the structure and biological function of a natural extracellular matrix can be simulated, and the directionally arranged nanofiber can also guide the migration, proliferation and differentiation of the cell better; most tissues and organs of humans are similar in form and structure to nanofibers, which provide the possibility for electrospun nanofibers for repair of tissues and organs. Biomedical high molecular PCL has excellent mechanical properties, but poor hydrophilicity and biological activity, and gelatin has biological activities such as cell adhesion and the like but lacks good mechanical properties. Therefore, the composite material combining the two materials has biological activity, good mechanical property, good biocompatibility and degradability, can be used as a carrier to enter a human body, and is easy to be absorbed.
Angiogenesis is the formation of blood vessels from de novo endothelial cell regeneration, a process of neovascularization, critical in development and subsequent physiological homeostasis. Given the limitations of current strategies to maintain therapeutic doses of growth factors and endothelial cell efficacy, stimulating angiogenesis during the wound healing process remains a significant clinical challenge. The tissue defect causes the lack of blood vessels, so that oxygen and other nutritional components cannot be transported normally, and therefore, the healing of wounds is also hindered to a certain extent. Vascular endothelial growth factor (vascular endothelial growth factor, VEGF) is a highly specific pro-vascular endothelial growth factor having the effect of promoting increased vascular permeability, vascular endothelial cell migration, proliferation and angiogenesis.
At present, the compounding of PCL and gelatin and the biological functional construction (such as angiogenesis) are one of hot spots in the field of tissue regeneration. But mainly uses the simple mixing of specific polypeptide and high molecular material, so that the effect of long-acting slow-release factor can not be reached, and the tissue regeneration effect is limited. Covalent bonds (covalent bonds) are chemical structures where two or more atoms share their outer electrons, ideally reaching an electron saturated state, and thus constituting a relatively stable chemical structure. The material obtained by adopting the covalent grafting method not only can obtain stable effect, but also can obtain the biomedical material with controllable mechanical property and controllable grafting rate by controlling the reaction condition.
In view of the above, the invention provides a preparation method for organically combining a covalently-bonded Vascular Endothelial Growth Factor (VEGF) methacryloyl gelatin film and a directional active nanofiber film to construct a bioactive composite film which has mechanical flexibility and can actively promote angiogenesis, and the preparation method is used in the field of full-layer skin wound repair.
Disclosure of Invention
Aiming at the defects in the research field, the invention provides a preparation method of a flexible directional nano composite membrane capable of promoting blood vessel regeneration, and the obtained composite membrane has controllable mechanical property and good biocompatibility, has the function of promoting vascularization, and has good application prospect in regenerative medicine and clinical treatment.
In order to achieve the above purpose, the following technical scheme is adopted:
(1) Adding sodium carbonate into deionized water, adjusting the pH to 7-10, adding gelatin according to the proportion of 50-200g/L, heating and continuously stirring to enable the gelatin to be fully dissolved, adding methacrylic anhydride, wherein the volume-mass ratio of the methacrylic anhydride to the gelatin is 1:1-3:1, continuously stirring for 1-8 hours at the temperature of 40-50 ℃, dialyzing at normal temperature, and freeze-drying after the dialysis is completed to obtain the methacrylic acid acylated gelatin. The reaction chemical formula is as follows:
(2) Adding methacrylic acid acylated gelatin into deionized water according to the proportion of 50-200g/L, mixing, adding succinic anhydride according to the volume-mass ratio of 1:1-3:1 of succinic anhydride to methacrylic acid acylated gelatin, heating and continuously stirring, dialyzing at normal temperature after the reaction is complete, and freeze-drying after the dialysis is completed to obtain the modified methacrylic acid acylated gelatin-COOH. The reaction chemical formula is as follows:
(3) Dissolving 50-200g/L of modified methacrylic acid acylated gelatin-COOH in Phosphate Buffer Saline (PBS), and adding a mixture of 1- (3-dimethylaminopropyl) -3-Ethylcarbodiimide (EDC) and N-hydroxysuccinimide (NHS) according to a proportion of 0.1-0.5 g/L; activating and continuously stirring gently, then adding the vascular endothelial growth factor according to the proportion of 0.1-0.4 g/L, mixing and stirring for 6-24 hours, dialyzing at normal temperature, and freeze-drying after the dialysis is finished to obtain the covalent grafted methacrylic acid acylated gelatin-vascular endothelial growth factor. The reaction chemical formula is as follows:
(4) Mixing phenyl-2, 4, 6-trimethylbenzoyl lithium phosphite (LAP) and a phosphate buffer salt solution in a light-shielding condition according to a proportion of 5-20 g/L, magnetically stirring for 1-8 hours at 50 ℃ to prepare a phenyl-2, 4, 6-trimethylbenzoyl lithium phosphite solution, adding methacrylic acid acylated gelatin-vascular endothelial growth factor into the phenyl-2, 4, 6-trimethylbenzoyl lithium phosphite solution according to a proportion of 50-200g/L, magnetically stirring for 1-8 hours at 50 ℃, and uniformly stirring to obtain the methacrylic acid acylated gelatin-vascular endothelial growth factor hydrogel.
(5) And dissolving the polycaprolactone and gelatin in a hexafluoroisopropanol solution according to a ratio of 50-70 g/L, rapidly stirring at 40 ℃, wherein the mass ratio of the polycaprolactone to the gelatin is 1:1-2:1, preparing the polycaprolactone-gelatin flexible oriented nanofiber membrane by using an electrostatic spinning method, washing with a phosphate buffer salt solution, and naturally drying for later use.
(6) Spreading the methacrylic acid acylated gelatin-vascular endothelial growth factor hydrogel obtained in the step (4) on a polycaprolactone-gelatin flexible directional nanofiber membrane, immersing vascular endothelial growth factor into fiber pores along with the hydrogel, carrying out in-situ photocrosslinking solidification under blue light irradiation, and carrying out vacuum drying to obtain the flexible directional nanofiber composite membrane with the vascular endothelial growth factor concentration gradient.
Preferably, the conditions of the dialysis in the steps (1) to (3) are as follows: dialyzing for 5-10 days at normal temperature, changing deionized water every 12 hours, and slowly and gently stirring during the dialysis.
Preferably, the freeze-drying temperatures in the steps (1) - (3) are as follows: -80 ℃.
Preferably, in the step (3), the mass ratio of the 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide to the N-hydroxysuccinimide is 1:1-1:3.
Preferably, the conditions of electrospinning in step (5) of the present invention are: the flow rate of the solution is 0.5-2 ml/h, the voltage is 10-20 KV, the rotating speed of a high-speed roller collector is 2000-3000 rpm, so that fibers are arranged in an oriented mode, the ambient humidity is controlled to be about 30%, and the distance between the collector and a spinneret is 15-20 cm.
Preferably, in the step (6) of the present invention, the wavelength of the blue light is 405 to 460 nm.
Compared with the prior art, the invention has the advantages that:
(1) The composite membrane has good biocompatibility, has bioactivity, takes the PCL-gelatin nanofiber membrane as a substrate membrane, and is further crosslinked on the membrane to obtain the composite membrane of the methacrylic acid acylated gelatin-vascular endothelial growth factor hydrogel and the nanofiber membrane with high mechanical strength.
(2) The invention adopts a light response mode to generate a crosslinked network for the natural polymer hydrogel, has high production efficiency and can be prepared in batches.
(3) The layered structure of the composite membrane imitates the physiological structure of natural skin, namely an epidermis layer and a dermis layer, and the microstructure of the composite membrane is similar to the extracellular matrix structure, so that the composite membrane has the bionic biological characteristic.
(4) The existing strategy of loading VEGF by an electrostatic spinning method can only obtain VEGF uniformly distributed on a membrane, but the invention can obtain the composite membrane with VEGF concentration gradient by controlling the grafting rate of VEGF in hydrogel and combining the hydrogel layer with the electrostatic spinning membrane.
(5) The invention is a double-layer composite membrane, and the VEGF is grafted through a covalent bond, so that the problem of short-time explosive release of VEGF is solved, the purposes of stably and long-acting slow release of VEGF and promotion of regeneration of blood vessels and skin can be achieved, and a new thought and method are provided for preparation of a multilayer biological scaffold and effective slow release of biological factors in tissue engineering.
Drawings
FIG. 1 is a reaction scheme for modifying gelatin in example 1;
FIG. 2 shows H-NMR of hydrogen nuclear magnetic resonance chart of unmodified gelatin in example 1;
FIG. 3 is a hydrogen nuclear magnetic resonance chart H-NMR of methacryloylated gelatin in example 1;
FIG. 4 is an SEM image of the microstructure of a flexible oriented nanofiber substrate membrane of example 1;
FIG. 5 is a physical diagram of the overall morphology of the flexible oriented nanofiber composite membrane of example 1;
fig. 6 is an SEM image of the microstructure of the flexible oriented nanofiber composite membrane of example 1 (a) front side and (b) side.
Detailed Description
The invention will be described in further detail with reference to the drawings and the detailed description, but the scope of the invention is not limited to the description.
Example 1
The preparation method of the flexible directional nano composite membrane capable of promoting the regeneration of blood vessels specifically comprises the following steps:
(1) Adding sodium carbonate into deionized water, regulating pH to 7.0, adding gelatin according to the proportion of 100g/L, heating and continuously stirring to enable gelatin to be fully dissolved, adding methacrylic anhydride (the reaction formula is shown in figure 1), wherein the volume-mass ratio of methacrylic anhydride to gelatin is 2:1, continuously stirring for 8 hours at 50 ℃, dialyzing for 5 days at normal temperature, changing deionized water every 12 hours, slowly and gently stirring during dialysis, and freeze-drying at-80 ℃ for 36 hours after dialysis is completed to obtain methacrylic acid acylated gelatin, wherein nuclear magnetic resonance spectra before and after modification are shown in figures 2 and 3.
(2) Adding the methacrylic acid acylated gelatin into deionized water according to the proportion of 100g/L, mixing, adding succinic anhydride according to the proportion of 1.6:1 of the volume mass ratio of succinic anhydride to the methacrylic acid acylated gelatin, stirring at 50 ℃ for reaction for 24 hours, dialyzing for 5 days at normal temperature, changing deionized water every 12 hours, slowly and gently stirring during dialysis, and freeze-drying at-80 ℃ after dialysis is completed to obtain the modified methacrylic acid acylated gelatin-COOH.
(3) Dissolving 50g/L of modified methacrylic acid acylated gelatin-COOH in phosphate buffer salt solution, adding 0.1g/L of 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide, and adding 0.1g/L of N-hydroxysuccinimide; activating and continuously and gently stirring, then adding vascular endothelial growth factor according to the proportion of 0.1g/L, mixing and stirring for 8 hours, dialyzing for 5 days at normal temperature, changing deionized water every 12 hours, slowly and gently stirring during dialysis, and freeze-drying at-80 ℃ to obtain the covalent grafted methacrylic acid acylated gelatin-vascular endothelial growth factor.
(4) Mixing phenyl-2, 4, 6-trimethylbenzoyl lithium phosphite and phosphate buffer salt solution according to the proportion of 5g/L under the dark condition, magnetically stirring for 2 hours at 50 ℃ to prepare phenyl-2, 4, 6-trimethylbenzoyl lithium phosphite solution, adding methacrylic acid acylated gelatin-vascular endothelial growth factor into the phenyl-2, 4, 6-trimethylbenzoyl lithium phosphite solution according to the proportion of 50g/L, magnetically stirring for 8 hours at 50 ℃ to obtain methacrylic acid acylated gelatin-vascular endothelial growth factor hydrogel after uniform stirring.
(5) And (3) dissolving Polycaprolactone (PCL) and gelatin in a hexafluoroisopropanol solution according to a ratio of 60g/L, rapidly stirring at 40 ℃, wherein the mass ratio of the polycaprolactone to the gelatin is 1:1, and preparing the PCL-gelatin flexible oriented nanofiber membrane by using an electrostatic spinning method (the electrostatic spinning method is adopted, the solution flow rate is 2ml/h, the voltage is 15KV, the rotating speed of a high-speed roller collector is 2000rpm, the environmental humidity is controlled to be about 30%, the distance between the collector and a spinneret is 20 cm), washing with a phosphate buffer salt solution, and naturally drying to obtain the PCL-gelatin electrostatic spinning flexible oriented nanofiber membrane. The surface morphology is shown in fig. 4, and the characteristic that the nanofiber membrane presents directional arrangement can be observed, and the fibers are in the nanometer scale (300-500 nanometers).
(6) Spreading the methacrylic acid acylated gelatin-vascular endothelial growth factor hydrogel obtained in the step (4) on a polycaprolactone-gelatin flexible directional nanofiber membrane, immersing VEGF into pores of the fiber along with the hydrogel, carrying out in-situ photocrosslinking curing under blue light irradiation of 405nm, and carrying out vacuum drying to obtain the flexible directional nanofiber composite membrane with VEGF concentration gradient. The overall appearance and flexibility of the composite film are shown, and as shown in fig. 5, the overall flexibility of the composite film is good; the surface morphology is shown in fig. 6, and it can be observed that the hydrogel layer is uniformly covered on the nanofiber membrane and immersed in the fiber pores to form a double-layer composite membrane structure.
Example 2
(1) Adding sodium carbonate into deionized water, regulating pH to 10, adding gelatin according to the proportion of 50g/L, heating and continuously stirring to enable the gelatin to be fully dissolved, adding methacrylic anhydride, wherein the volume mass ratio of the methacrylic anhydride to the gelatin is 1:1, continuously stirring for 4 hours at 40 ℃, dialyzing for 8 days at normal temperature, changing deionized water every 12 hours, slowly and gently stirring during dialysis, and freeze-drying at-80 ℃ to obtain the methacrylic acid acylated gelatin.
(2) Adding the methacrylic acid acylated gelatin into deionized water according to the proportion of 200g/L, mixing, adding succinic anhydride according to the proportion of 1:1 of the volume mass ratio of succinic anhydride to the methacrylic acid acylated gelatin, heating and continuously stirring, dialyzing for 8 days at normal temperature until the reaction is complete, changing deionized water every 12 hours, slowly and gently stirring during the dialysis, and freeze-drying at-80 ℃ to obtain the modified methacrylic acid acylated gelatin-COOH after the dialysis is completed.
(3) Dissolving 100g/L of modified methacrylic acid acylated gelatin-COOH in phosphate buffer salt solution, adding 0.3g/L of 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide, and adding 0.3g/L of N-hydroxysuccinimide; activating and continuously and gently stirring, then adding vascular endothelial growth factor according to the proportion of 0.4g/L, mixing and stirring for 16 hours, dialyzing for 5 days at normal temperature, changing deionized water every 12 hours, slowly and gently stirring during dialysis, and freeze-drying at-80 ℃ to obtain the covalent grafted methacrylic acid acylated gelatin-vascular endothelial growth factor.
(4) Mixing phenyl-2, 4, 6-trimethylbenzoyl lithium phosphite and phosphate buffer salt solution according to the proportion of 10g/L under the dark condition, magnetically stirring for 6 hours at 50 ℃ to prepare phenyl-2, 4, 6-trimethylbenzoyl lithium phosphite solution, adding methacrylic acid acylated gelatin-vascular endothelial growth factor into the phenyl-2, 4, 6-trimethylbenzoyl lithium phosphite solution according to the proportion of 100g/L, magnetically stirring for 6 hours at 50 ℃ to obtain methacrylic acid acylated gelatin-vascular endothelial growth factor hydrogel.
(5) And (3) dissolving Polycaprolactone (PCL) and gelatin in a hexafluoroisopropanol solution according to a proportion of 50g/L, rapidly stirring at 40 ℃, wherein the mass ratio of the polycaprolactone to the gelatin is 1:2, and obtaining the PCL-gelatin flexible oriented nanofiber membrane by using an electrostatic spinning method (the electrostatic spinning method is that the solution flow rate is 0.5ml/h, the voltage is 20KV, the rotating speed of a high-speed roller collector is 2300rpm, the environmental humidity is controlled to be about 30%, the distance between the collector and a spinneret is 15 cm), washing with a phosphate buffer salt solution, and naturally drying. The surface morphology was similar to example 1, with the fibers being nanoscale (300-500 nm).
(6) And (3) spreading the methacrylic acid acylated gelatin-vascular endothelial growth factor hydrogel obtained in the step (4) on a polycaprolactone-gelatin flexible directional nanofiber membrane, immersing VEGF into pores of the fiber along with the hydrogel, carrying out in-situ photocrosslinking curing under the irradiation of 405nm blue light, and carrying out vacuum drying to obtain the flexible directional nanofiber composite membrane with VEGF concentration gradient, wherein the hydrogel layer can be observed to be uniformly covered on the nanofiber membrane and immersed into the fiber pores to form a double-layer composite membrane structure.
Example 3
The preparation method of the flexible directional nano composite membrane capable of promoting the regeneration of blood vessels specifically comprises the following steps:
(1) Adding sodium carbonate into deionized water, regulating pH to 9, adding gelatin according to the proportion of 200g/L, heating and continuously stirring to enable the gelatin to be fully dissolved, adding methacrylic anhydride, wherein the volume mass ratio of the methacrylic anhydride to the gelatin is 3:1, continuously stirring for 8 hours at 45 ℃, dialyzing for 10 days at normal temperature, changing deionized water every 12 hours, slowly and gently stirring during dialysis, and freeze-drying at-80 ℃ to obtain the methacrylic acid acylated gelatin.
(2) Adding methacrylic acid acylated gelatin into deionized water according to the proportion of 50g/L, mixing, adding succinic anhydride according to the proportion of 3:1 of the volume mass ratio of succinic anhydride to methacrylic acid acylated gelatin, heating and continuously stirring, dialyzing for 8 days at normal temperature until the reaction is complete, changing deionized water every 12 hours, slowly and gently stirring during the dialysis, and freeze-drying at-80 ℃ to obtain the modified methacrylic acid acylated gelatin-COOH after the dialysis is completed.
(3) Dissolving modified methacrylic acid acylated gelatin-COOH in phosphate buffer salt solution according to the proportion of 200g/L, and adding a mixture of 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide and N-hydroxysuccinimide according to the proportion of 0.5 g/L; activating and continuously stirring gently, adding vascular endothelial growth factor according to the proportion of 0.4g/L, mixing and stirring for 24 hours, dialyzing for 10 days at normal temperature, changing deionized water every 12 hours, slowly and gently stirring during dialysis, and freeze-drying at-80 ℃ after dialysis is completed to obtain the covalent grafted methacrylic acid acylated gelatin-vascular endothelial growth factor.
(4) Mixing phenyl-2, 4, 6-trimethylbenzoyl lithium phosphite and phosphate buffer salt solution according to the proportion of 20g/L under the dark condition, magnetically stirring for 6 hours at 50 ℃ to prepare phenyl-2, 4, 6-trimethylbenzoyl lithium phosphite solution, adding methacrylic acid acylated gelatin-vascular endothelial growth factor into the phenyl-2, 4, 6-trimethylbenzoyl lithium phosphite solution according to the proportion of 200g/L, magnetically stirring for 8 hours at 50 ℃, and uniformly stirring to obtain methacrylic acid acylated gelatin-vascular endothelial growth factor hydrogel.
(5) Dissolving Polycaprolactone (PCL) and gelatin in a hexafluoroisopropanol solution according to a ratio of 70g/L, rapidly stirring at 40 ℃, wherein the mass ratio of the polycaprolactone to the gelatin is 2:1, and obtaining the PCL-gelatin electrostatic spinning flexible oriented nanofiber membrane by using an electrostatic spinning method (the electrostatic spinning condition is that the solution flow rate is 1.5ml/h, the voltage is 10KV, the rotating speed of a high-speed roller collector is 2500rpm, the environmental humidity is controlled to be about 30%, the distance between the collector and a spinneret is 18 cm), washing with a phosphate buffer salt solution, and naturally drying; the surface morphology was similar to example 1, and the fibers were shown to be nanoscale (300-500 nm).
(6) Spreading the methacrylic acid acylated gelatin-vascular endothelial growth factor hydrogel obtained in the step (4) on a polycaprolactone-gelatin flexible directional nanofiber membrane, immersing VEGF into pores of the fiber along with the hydrogel, carrying out in-situ photocrosslinking curing under the irradiation of 465nm blue light, and carrying out vacuum drying to obtain the flexible directional nanofiber composite membrane with VEGF concentration gradient. It can be observed that the hydrogel layer uniformly covers the nanofiber membrane and is immersed in the fiber pores to form a double-layer composite membrane structure.
Claims (5)
1. The preparation method of the flexible directional nanofiber composite membrane for promoting the regeneration of blood vessels is characterized by comprising the following steps of:
(1) Adding sodium carbonate into deionized water, adjusting the pH to 7-10, adding gelatin according to the proportion of 50-200g/L, heating and continuously stirring to enable the gelatin to be fully dissolved, adding methacrylic anhydride, wherein the volume-mass ratio of the methacrylic anhydride to the gelatin is 1:1-3:1, continuously stirring for 1-8 hours at the temperature of 40-50 ℃, dialyzing at normal temperature, and freeze-drying after the dialysis is completed to obtain methacrylic acid acylated gelatin;
(2) Adding methacrylic acid acylated gelatin into deionized water according to the proportion of 50-200g/L, mixing, adding succinic anhydride according to the volume-mass ratio of 1:1-3:1 of succinic anhydride to methacrylic acid acylated gelatin, heating and continuously stirring, dialyzing at normal temperature until the reaction is complete, and freeze-drying after the dialysis is completed to obtain modified methacrylic acid acylated gelatin-COOH;
(3) Dissolving modified methacrylic acid acylated gelatin-COOH in phosphate buffer salt solution according to the proportion of 50-200g/L, and adding a mixture of 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide and N-hydroxysuccinimide according to the proportion of 0.1-0.5 g/L; activating and continuously stirring gently, then adding vascular endothelial growth factor according to the proportion of 0.1-0.4 g/L, mixing and stirring for 6-24 hours, dialyzing at normal temperature, and freeze-drying after the dialysis is finished to obtain the covalent grafted methacrylic acid acylated gelatin-vascular endothelial growth factor;
(4) Mixing phenyl-2, 4, 6-trimethylbenzoyl lithium phosphite and phosphate buffer salt solution in a light-shielding condition according to a proportion of 5-20 g/L, magnetically stirring for 1-8 hours at 50 ℃ to prepare phenyl-2, 4, 6-trimethylbenzoyl lithium phosphite solution, adding methacrylic acid acylated gelatin-vascular endothelial growth factor into the phenyl-2, 4, 6-trimethylbenzoyl lithium phosphite solution according to a proportion of 50-200g/L, magnetically stirring for 1-8 hours at 50 ℃, and uniformly stirring to obtain methacrylic acid acylated gelatin-vascular endothelial growth factor hydrogel;
(5) Dissolving polycaprolactone and gelatin in a hexafluoroisopropanol solution according to a ratio of 50-70 g/L, rapidly stirring at 40 ℃, wherein the mass ratio of the polycaprolactone to gelatin is 1:1-2:1, preparing a polycaprolactone-gelatin flexible oriented nanofiber membrane by using an electrostatic spinning method, washing with a phosphate buffer salt solution, and naturally drying for later use;
(6) And (3) spreading the methacrylic acid acylated gelatin-vascular endothelial growth factor hydrogel obtained in the step (4) on a polycaprolactone-gelatin flexible directional nanofiber membrane, carrying out in-situ photocrosslinking solidification under blue light irradiation, and carrying out vacuum drying to obtain the flexible directional nanofiber composite membrane.
2. The method for preparing a flexible oriented nanofiber composite membrane for promoting vascular regeneration according to claim 1, wherein the method comprises the following steps: the dialysis conditions in the steps (1) - (3) are as follows: dialyzing for 5-10 days at normal temperature, changing deionized water every 12 hours, and slowly and gently stirring during the dialysis.
3. The method for preparing a flexible oriented nanofiber composite membrane for promoting vascular regeneration according to claim 1, wherein the method comprises the following steps: in the step (3), the mass ratio of the 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide to the N-hydroxysuccinimide is 1:1-1:3.
4. The method for preparing a flexible oriented nanofiber composite membrane for promoting vascular regeneration according to claim 1, wherein the method comprises the following steps: the conditions of the electrostatic spinning in the step (5) are as follows: the flow rate of the solution is 0.5-2 ml/h, the voltage is 10-20 KV, the rotating speed of the high-speed roller collector is 2000-3000 rpm, the fibers are aligned, the ambient humidity is controlled at 30%, and the distance between the collector and the spinneret is 15-20 cm.
5. The method for preparing a flexible oriented nanofiber composite membrane for promoting vascular regeneration according to claim 1, wherein the method comprises the following steps: the wavelength of the blue light in the step (6) is 405-460 nm.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111177371.3A CN114146227B (en) | 2021-10-09 | 2021-10-09 | Preparation method of flexible directional nanofiber composite membrane capable of promoting vascular regeneration |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111177371.3A CN114146227B (en) | 2021-10-09 | 2021-10-09 | Preparation method of flexible directional nanofiber composite membrane capable of promoting vascular regeneration |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114146227A CN114146227A (en) | 2022-03-08 |
CN114146227B true CN114146227B (en) | 2023-05-05 |
Family
ID=80462562
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111177371.3A Active CN114146227B (en) | 2021-10-09 | 2021-10-09 | Preparation method of flexible directional nanofiber composite membrane capable of promoting vascular regeneration |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114146227B (en) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102001120B1 (en) * | 2017-06-29 | 2019-07-16 | 서울대학교산학협력단 | Complex of nanofiber and hydrogel and a scaffold for tissue regeneration |
CN112194798A (en) * | 2020-10-21 | 2021-01-08 | 深圳大洲医学科技有限公司 | Modification method of gelatin |
CN112569399B (en) * | 2020-12-11 | 2022-02-01 | 中山大学 | Photo-crosslinking/electrostatic spinning preparation and application of hydrogel composite scaffold with double-layer skin structure |
-
2021
- 2021-10-09 CN CN202111177371.3A patent/CN114146227B/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN114146227A (en) | 2022-03-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Li et al. | Advanced electrospun hydrogel fibers for wound healing | |
Fan et al. | Silk materials for medical, electronic and optical applications | |
Dahlin et al. | Polymeric nanofibers in tissue engineering | |
Muthukrishnan | An overview on electrospinning and its advancement toward hard and soft tissue engineering applications | |
Chen et al. | Three-dimensional layered nanofiber sponge with in situ grown silver-metal organic framework for enhancing wound healing | |
CN105536055B (en) | A kind of shape memory type high resiliency active nano fibrous framework and its application | |
WO2020133668A1 (en) | Nerve conduit of magnesium filament and silk compositely woven structure and preparation method for nerve conduit | |
CN103948974A (en) | Drug-loading type guided tissue regeneration membrane and preparation method thereof | |
CN104524643A (en) | Halloysite-nanotube-containing drug-loaded type guide tissue regeneration membrane and preparation method thereof | |
CN102488929B (en) | Regenerated silk fibroin tissue engineering scaffold containing vascular endothelial growth factor and preparation method thereof | |
Maleki et al. | Nanofiber-based systems intended for diabetes | |
CN109758611B (en) | Method for preparing active biological tissue engineering scaffold by solvent spraying | |
CN111962210B (en) | Polycaprolactone/methacryloylated elastin nanofiber composite membrane and preparation method and application thereof | |
CN111228484B (en) | Application of xonotlite and composite biological material containing xonotlite | |
Chen et al. | Bio-inspired hydrogels with fibrous structure: A review on design and biomedical applications | |
CN107737364A (en) | A kind of wound dressing and preparation method thereof | |
CN109675119A (en) | A kind of artificial dermis and preparation method thereof for chronic wound treatment | |
de Lima et al. | Electrospinning of hydrogels for biomedical applications | |
Zhang et al. | Electrospun piezoelectric scaffold with external mechanical stimulation for promoting regeneration of peripheral nerve injury | |
Sadeghi et al. | Multilayered 3-D nanofibrous scaffold with chondroitin sulfate sustained release as dermal substitute | |
Farahani et al. | Silk-based biopolymers promise extensive biomedical applications in tissue engineering, drug delivery, and BioMEMS | |
Dong et al. | Electrospun nanofibrous membranes of recombinant human collagen type III promote cutaneous wound healing | |
CN114146227B (en) | Preparation method of flexible directional nanofiber composite membrane capable of promoting vascular regeneration | |
Sharifi et al. | Cell-loaded genipin cross-linked collagen/gelatin skin substitute adorned with zinc-doped bioactive glass-ceramic for cutaneous wound regeneration | |
Mohammadzadehmoghadam et al. | Electrospinning of silk fibroin-based nanofibers and their applications in tissue engineering |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240613 Address after: No. 547, Building 9, Yunshang Town, Wujiaying Street, Chenggong District, Kunming City, Yunnan Province, 650500 Patentee after: Lebohai Biotechnology (Kunming) Co.,Ltd. Country or region after: China Address before: 650093 No. 253, Xuefu Road, Wuhua District, Yunnan, Kunming Patentee before: Kunming University of Science and Technology Country or region before: China |